Portola Pharmaceuticals, Inc. Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis®
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced new interim findings from a Phase 2 proof-of-concept study of its investigational Factor Xa inhibitor antidote, Andexanet alfa, in healthy volunteers who received the Factor Xa inhibitor Eliquis® (apixaban). Andexanet alfa was administered intravenously as a bolus followed by a continuous infusion for up to two hours. Data from this study showed a rapid and nearly complete reversal of the anticoagulation effect of Eliquis measured at two minutes following completion of the bolus, which was sustained during infusion for up to two hours.
Help employers find you! Check out all the jobs and post your resume.